Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.2 USD | -4.35% | -5.58% | +13.40% |
Mar. 04 | North American Morning Briefing : Stock Futures -2- | DJ |
Feb. 28 | Lyell Immunopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Business Summary
Number of employees: 224
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
T-Cell Therapies
100.0
%
| 85 | 100.0 % | 0 | 100.0 % | -99.85% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 85 | 100.0 % | 0 | 100.0 % | -99.85% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Lynn Seely
CEO | Chief Executive Officer | 65 | 21-04-30 |
Charles Newton
DFI | Director of Finance/CFO | 53 | 21-01-31 |
Stephen Hill
COO | Chief Operating Officer | 53 | 19-05-31 |
Gary Lee
CTO | Chief Tech/Sci/R&D Officer | 47 | 22-01-30 |
Richard D. Goold
CTO | Chief Tech/Sci/R&D Officer | 64 | 19-03-31 |
Ellen Rose
IRC | Investor Relations Contact | - | 21-03-31 |
Matthew Lang
LAW | General Counsel | 48 | 23-07-04 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Lynn Seely
CEO | Chief Executive Officer | 65 | 21-04-30 |
Robert Nelsen
BRD | Director/Board Member | 60 | 18-08-31 |
Otis Brawley
BRD | Director/Board Member | 64 | 21-03-31 |
William Rieflin
BRD | Director/Board Member | 64 | 20-04-30 |
Richard Klausner
CEO | Chief Executive Officer | 72 | 18-05-31 |
Director/Board Member | 63 | 18-07-31 | |
Hans Bishop
BRD | Director/Board Member | 59 | 18-07-31 |
Elizabeth Nabel
BRD | Director/Board Member | 72 | 21-03-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 254,096,311 | 206,999,293 ( 81.46 %) | 0 | 81.46 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
CERo Therapeutics Holdings, Inc.
3.35% | 499,999 | 3.35% | 1,534,997 $ |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.40% | 561M | |
-2.26% | 103B | |
+1.41% | 95.71B | |
+0.79% | 22.02B | |
-17.84% | 20.9B | |
-11.11% | 17.85B | |
-42.83% | 16.21B | |
-17.63% | 15.52B | |
+4.55% | 13.86B | |
+32.11% | 12.04B |
- Stock Market
- Equities
- LYEL Stock
- Company Lyell Immunopharma, Inc.